Effexor XR for sale
The mechanism of action is caused by the ability of the drug potentiate the transmission of nerve impulses in the central nervous system.
The active substance is Venlafaxine. Other drugs with Venlafaxine active ingredient: Velaxin, Venlafaxine, Efectin, Efectin Depo.
Effexor XR is applied in the treatment of depression with associated anxiety, also for relapse prevention, including in case of recurrent depressive disorder (in a hospital or in an outpatient setting).
Effexor XR belongs to a group of antidepressants. It is a strong inhibitor of serotonin and noradrenaline reuptake and weak inhibitor of dopamine reuptake. Indications to the drug using include the treatment of depression and prevention of its recurrence. The drug is manufactured in the form of powder in cardboard boxes, tablets and capsules. Daily dose is 0.225 (in three receptions). Effexor XR is used in meal times, squeezed water. Side effects include dizziness, asthenia, muscle weakness, convulsions, lethargy, dizziness and other. Effexor XR shouldn't be taken when stenocardia, arterial hypertension, narrow-angle glaucoma, hyponatraemia, hypovolemia, in the period of lactation and during pregnancy. Blood pressure control is a mandatory component during the drug treatment. An overdose causes dizziness, decreased blood pressure, sinus and ventricular tachycardia, a violation of consciousness, convulsions and death. Effexor XR increases the anticoagulant effect of warfarin. It enhances the effect of ethanol on the psychomotor reactions. The drug reduces the total clearance of haloperidol with oral administration.
Fertility treatment: Vitamin D may influence success rate
A new meta-analysis has found a link between lower blood concentrations of vitamin D and reduced success rates in assisted reproduction therapy.Sat, 18 Nov 2017, 12:00
Do you gain weight with a birth control implant?
A look at birth control implants and weight gain. Included is information on the causes of weight gain and other birth control implant side effects.Sat, 18 Nov 2017, 13:00